Comparative Pharmacology
Head-to-head clinical analysis: DEPACON versus DILANTIN 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPACON versus DILANTIN 125.
DEPACON vs DILANTIN-125
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases GABA concentration in the brain by inhibiting GABA transaminase and blocking voltage-gated sodium channels.
Phenytoin stabilizes neuronal membranes by promoting voltage-gated sodium channel inactivation, reducing high-frequency neuronal firing and seizure propagation.
10-15 mg/kg/day IV or orally divided every 8 hours; maximum 60 mg/kg/day.
300-400 mg per day orally in divided doses (e.g., 100 mg three times daily); loading dose 1 g orally divided into three doses given at 2-hour intervals, then 100 mg every 6-8 hours for first 24 hours.
None Documented
None Documented
10–16 hours; neonates 20–30 hours; patients with liver disease up to 18 hours; decreased half-life in patients on enzyme-inducing antiepileptics (e.g., phenytoin, carbamazepine) to 4–9 hours.
Terminal half-life: 7-42 hours (mean 22 hours) in adults; dose-dependent due to saturable metabolism. Steady-state reached in 7-10 days.
Primarily renal: >90% of a dose is excreted in urine as valproic acid glucuronide (30–50%), 3-oxo-valproic acid (30–40%), and other metabolites. Less than 3% excreted unchanged. Minor fecal elimination (≈5%).
Renal: 70% as metabolites (mainly HPPA glucuronide and sulfate), 5-10% as unchanged drug. Fecal: 30% (minor).
Category C
Category C
Anticonvulsant
Anticonvulsant